Analyst Kyle Rose works at CANACCORD and is covering the the Healthcare sector with 502 price targets and ratings documented since 2012 spanning on 26 stocks.
Kyle Rose's average stock forecast success ratio is 48.25% with an average time for price targets to be met of 172.24 days.
Most recent stock forecast was given on GMED, Globus Medical, Inc at 30-Mar-2023.
Analyst best performing recommendations are on TELA (TELA BIO INC.).
The best stock recommendation documented was for XENT at 1/11/2021. The price target of $25 was fulfilled within 2 days with a profit of $2.78 (12.51%) receiving and performance score of 62.56.
Average potential price target upside
Currently, out of the existing stock ratings of Kyle Rose - 7 which are a Buy (53.85%), 5 which are a Hold (38.46%), 1 which are a Sell (7.69%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
19
$4.16 (28.03%)
18
5 days ago
4/9 (44.44%)
$3.51 (30.50%)
322
Buy
20
$5.16 (34.77%)
20
2 months 30 days ago
0/3 (0%)
$6.42 (56.58%)
Buy
20
$5.16 (34.77%)
24
4 months 19 days ago
6/9 (66.67%)
$5.92 (108.88%)
346
Buy
17
$2.16 (14.56%)
17
4 months 22 days ago
8/16 (50%)
$4.09 (44.94%)
188
Buy
12
$-2.84 (-19.14%)
7 months 19 days ago
1/1 (100%)
$2.1 (21.21%)
78
